Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

Dr. George Tidmarsh, the FDA drug regulator who was placed on leave and complained of a “toxic” work environment in an ...

Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...

Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...

George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...

Aurinia Pharmaceuticals ( ($AUPH) ) has released its Q3 earnings. Here is a breakdown of the information Aurinia Pharmaceuticals presented to its ...

RBC Capital downgraded Aurinia Pharmaceuticals (AUPH) to Sector Perform from Outperform with a price target of $15, up from $9. The firm says the ...

The top drug regulator at the Food and Drug Administration (FDA) resigned Sunday, according to officials, after being accused ...

The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, resigned on ...

Executive accused of making false statements about a drug and soliciting a bribe. Baidu’s Apollo Go hits driverless ride ...

Aurinia Pharmaceuticals Inc (AUPH) reports significant growth in Lupkynis sales and raises its 2025 sales guidance, while navigating legal and regulatory hurdles.